AstraZeneca PLC
AZNNYSEHealthcare● Active
$181.92
$-4.03(-2.17%)
Market Cap$282.1B
P/E Ratio—
52W High$212.71
52W Low$137.22
AstraZeneca PLC (AZN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AZN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
$2.58
Est. $2.57 · +0.4%
Revenue
$15.29B
Est. $14.93B · +2.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
AZN reports quarterly as a NYSE-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.00B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.00B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 27, 2026 | $2.22 | — | — | — | $15.47B | — |
| — Q2 FY2026 | Apr 29, 2026 | $2.57 | $2.58 | +0.4% | $15.29B | $14.93B | +2.4% |
| ▼ Q1 FY2026 | Feb 10, 2026 | $2.18 | $2.12 | -2.8% | $15.50B | $15.44B | +0.4% |
| ▲ Q4 FY2025 | Nov 6, 2025 | $2.29 | $2.38 | +3.9% | $15.19B | $15.42B | -1.5% |
| — Q3 FY2025 | Jul 29, 2025 | $2.16 | $2.18 | +0.9% | $14.46B | $14.76B | -2.1% |
| ▲ Q2 FY2025 | Apr 29, 2025 | $2.25 | $2.48 | +10.2% | $13.59B | $14.06B | -3.3% |
| ▲ Q1 FY2025 | Feb 6, 2025 | $2.07 | $2.10 | +1.4% | $14.89B | $13.34B | +11.6% |
| ▲ Q4 FY2024 | Nov 12, 2024 | $2.04 | $2.08 | +2.0% | $13.56B | $13.09B | +3.6% |
Q3 FY2026
Jul 27, 2026
EPS Actual
—
EPS Est.
$2.22
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026
EPS Actual
$2.58
EPS Est.
$2.57
EPS Surpr.
+0.4%
Revenue
$15.29B
Q1 FY2026
Feb 10, 2026Miss
EPS Actual
$2.12
EPS Est.
$2.18
EPS Surpr.
-2.8%
Revenue
$15.50B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$2.38
EPS Est.
$2.29
EPS Surpr.
+3.9%
Revenue
$15.19B
Q3 FY2025
Jul 29, 2025
EPS Actual
$2.18
EPS Est.
$2.16
EPS Surpr.
+0.9%
Revenue
$14.46B
Q2 FY2025
Apr 29, 2025Beat
EPS Actual
$2.48
EPS Est.
$2.25
EPS Surpr.
+10.2%
Revenue
$13.59B
Q1 FY2025
Feb 6, 2025Beat
EPS Actual
$2.10
EPS Est.
$2.07
EPS Surpr.
+1.4%
Revenue
$14.89B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
$2.08
EPS Est.
$2.04
EPS Surpr.
+2.0%
Revenue
$13.56B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $2.66 | $2.71 | $2.78 | 1 |
| Q3 FY2027 | $3.07 | $3.13 | $3.21 | 1 |
| Q2 FY2027 | $2.76 | $2.81 | $2.88 | 1 |
| Q1 FY2027 | $2.80 | $2.85 | $2.92 | 1 |
| Q4 FY2026 | $2.47 | $2.52 | $2.58 | 1 |
| Q3 FY2026 | $2.65 | $2.68 | $2.70 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $17.4B | $17.6B | $18.0B | 3 |
| Q3 FY2027 | $17.0B | $17.2B | $17.6B | 3 |
| Q2 FY2027 | $16.0B | $16.2B | $16.5B | 3 |
| Q1 FY2027 | $15.3B | $15.6B | $15.9B | 4 |
| Q4 FY2026 | $16.5B | $16.7B | $17.1B | 4 |
| Q3 FY2026 | $16.0B | $16.2B | $16.3B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 29, 2026 | +0.4% | $186.68 | $185.20 | -0.79% |
| ▼ Q1 FY2026 | Feb 10, 2026 | -2.8% | $188.01 | $193.10 | +2.71% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +3.9% | $162.30 | $169.00 | +4.13% |
| ▲ Q3 FY2025 | Jul 29, 2025 | +0.9% | $144.10 | $150.48 | +4.43% |
| ▲ Q2 FY2025 | Apr 29, 2025 | +10.2% | $138.76 | $144.94 | +4.45% |
| ▲ Q1 FY2025 | Feb 6, 2025 | +1.4% | $134.67 | $151.50 | +12.50% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +2.0% | $126.80 | $128.41 | +1.27% |
| ▲ Q3 FY2024 | Jul 25, 2024 | +0.5% | $158.82 | $155.48 | -2.10% |
Q2 FY2026-0.79%
Report Date
Apr 29, 2026
EPS Beat/Miss
+0.4%
Price Before
$186.68
Price After
$185.20
Q1 FY2026+2.71%
Report Date
Feb 10, 2026
EPS Beat/Miss
-2.8%
Price Before
$188.01
Price After
$193.10
Q4 FY2025+4.13%
Report Date
Nov 6, 2025
EPS Beat/Miss
+3.9%
Price Before
$162.30
Price After
$169.00
Q3 FY2025+4.43%
Report Date
Jul 29, 2025
EPS Beat/Miss
+0.9%
Price Before
$144.10
Price After
$150.48
Q2 FY2025+4.45%
Report Date
Apr 29, 2025
EPS Beat/Miss
+10.2%
Price Before
$138.76
Price After
$144.94
Q1 FY2025+12.50%
Report Date
Feb 6, 2025
EPS Beat/Miss
+1.4%
Price Before
$134.67
Price After
$151.50
Q4 FY2024+1.27%
Report Date
Nov 12, 2024
EPS Beat/Miss
+2.0%
Price Before
$126.80
Price After
$128.41
Q3 FY2024-2.10%
Report Date
Jul 25, 2024
EPS Beat/Miss
+0.5%
Price Before
$158.82
Price After
$155.48
Avg Beat Reaction+3.41%
Avg Miss Reaction+2.71%
Beat Rate7 / 8 quarters
Largest Move+12.50% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AZN ends December
AstraZeneca PLC (AZN) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $2.58 (in line with the analyst consensus of $2.57). The next AZN earnings date is expected around September 1, 2026.
Each quarter, investors track AZN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AZN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AZN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AZN earnings · 4 questionsAstraZeneca PLC's next earnings report is expected around September 1, 2026. AZN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AZN historically reports after market close (AMC).
AZN earnings datewhen is AZN earningsAZN next earnings datewhen does AZN report earningsAZN earnings calendar
▸ Source: FMP · AstraZeneca PLC SEC filings · US GAAP · AstraZeneca PLC SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026